



ELEKTA FINALIZES THE ACQUISITION OF 3D LINE MEDICAL SYSTEMS

PRESS RELEASE

Stockholm, May 3, 2007

Elekta, world leader in advanced radiation therapy, comprehensive cancer management and non-invasive treatment of brain disorders, have today finalized the acquisition of 3D Line Medical Systems S.r.l.

Through this acquisition, Elekta adds a highly qualified R&D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy with extreme precision and optimized dose distribution.

The company has 35 employees and consultants, of whom most are based in Milan, Italy. Among the 3D Line technologies commercially available today, are the ERGO++, a specialized treatment planning system for stereotactic radiation therapy and dynamic IMRT and also the DYNART™ series of micro-sized multi leaf collimators. In 2006, 3D Line's net sales totaled EUR 6 M with a moderate profit.

Elekta will pay EUR 10 M in cash for assets in 3D Line Medical Systems related to radiation therapy and up to a maximum of EUR 8 M, based on future performance over the coming 3 years. Elekta expects to consolidate 3D Line into its accounts from May 1, 2007.

"3D Line's current products as well as the R&D pipeline fit extremely well into the Elekta Group and the acquisition is an important step in the further advancement of radiation therapy", says Tomas Puusepp, President and CEO of Elekta. "3D Line's cutting edge technology for dynamic beam shaping, arc treatment and stereotactic treatment planning is an excellent addition to Elekta's world-leading solutions for advanced radiation therapy and with the increased global sales reach within Elekta, we will be able to exploit the increasing demand for these products", Tomas Puusepp concludes.

For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000
e-mail: peter.ejemyr@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com and for more information about IMPAC Medical System please visit www.impac.com.